In May 2024, the DoP received an anonymous complaint alleging AbbVie Healthcare India flew 30 doctors—experts in Botox and Juvederm—to Paris and Monaco. It said the firm treated the doctors to “extravagant pleasure trips under the guise of conferences", that AbbVie purportedly flew doctors to a medical conference held in these locations. DoP’s order says AbbVie violated the Uniform Code …
A market rotation is playing out across large pharmaceutical companies, with industry laggards such as Bristol Myers Squibb soaring in recent weeks and richly valued obesity plays Eli Lilly and Novo Nordisk sinking. Executives told analysts that despite the “net unfavorable impact" from the law in 2025, the company expects revenue to grow over 3% next year and then 5% …
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth. Elahere brought in $105.2 million in revenue in …
